Clinical research of Michael J. Krowka, M.D., broadly covers the lung abnormalities that are caused by liver disease. The lung abnormalities can be very important in that the decisions to proceed with liver transplantation may depend on the severity of the following lung problems:
- Hepatopulmonary syndrome (HPS). This is a liver-induced pulmonary vasodilation problem causing severely low oxygen levels in the blood. Investigation focuses on the factors that dilate blood vessels. This syndrome is reversible by liver transplantation.
- Portopulmonary hypertension (POPH). This is a liver-induced pulmonary vasoconstriction problem causing pulmonary artery high blood pressure and right heart failure. Investigation focuses on medical treatments to allow safe liver transplant. This syndrome may or may not resolve after liver transplant.
- Alpha-1 antitrypsin deficiency. This inherited disorder can cause deficiency of a circulating protein made in the liver that protects the lung. Deficiency of this blood protein (caused by an accumulation in the liver cells, causing cirrhosis and the need for liver transplantation) results in lung damage, mainly emphysema. Investigation focuses on normalization of the blood protein level after liver transplantation and the subsequent effect on the lungs.
Dr. Krowka's research projects involve patients at Mayo Clinic's campuses in Minnesota, Arizona and Florida.
- Pulmonary hypertension associated with liver diseases
Mayo Clinic Locations
Fellow - PulmonaryMayo Graduate School of Medicine, Mayo Clinic College of Medicine
Resident - Internal MedicineEvanston Hospital, Northwestern University Medical School
Internship - MedicineEvanston Hospital, Northwestern University Medical School
MD - MedicineUniversity of Nevada, Reno
MS - Educational Foundations & CounselingUniversity of Nevada, Las Vegas
BS - MathematicsNorthern Illinois University
Activities and Honors